BUSINESS BRIEF

It is an established pharmaceutical company specializing in generic drugs, over-the-counter medicines, prescription formulations, cosmeceuticals, and nutraceuticals. The company operates in multiple therapeutic areas, including cardiovascular, neurology, anti-infective, analgesic, anti-ulcerants, ortho, derma, diabetic care, and nutraceuticals.

  • With a strong presence across 180 districts in India, the company has achieved consistent growth without external funding.
  • The company is in growth-stage that operate in market with high barriers to entry. The businesses has strong fundamentals, reasonable profit margins and significant growth potential.
  • It is into E-Commerce & Retailing business also

Manufacturing & Compliance:

  • In-house nutritional supplements manufacturing facility with FSSA & USFDA registrations
  • Outsourced production for all other drug formulations
  • Fully compliant with WHO-GMP, FDA
  • Patents under application process, with multiple registered brands

Highlights:

  • 400+ products in the market
  • Domestic (90%) & Export (10%) market share
  • Registered and marketed in international markets
  • Competitive edge through strong brand presence and differentiation
  • The company is now strategically planning for an SME public listing by 2026

Products & Services

  • Pharmaceutical products
  • Nutraceutical products
  • Animal Healthcare products (Specialized focus in poultry)
Proposal
Icon

Industry

Pharmaceuticals

Icon

Sub Industry

Pharmaceutical Manufacturing (Formulation)

Icon

Nature of Business

B2B, B2C

Icon

Sector

Manufacturing (Own Brand & Contract Manufacturing)

Icon

Reason for sell-off

Strategic Realignment or Pursuing New Opportunities

Icon

Location

India

Icon

Region

Southern

Icon

Open For Dilution

100 % (Complete Buyout)

Icon

Top Customer

Icon

Deal Size

INR 60 - 70 Cr

Icon

Justification

Based on market multiple

Business Operation Information
Financial Information
2025 (in INR Cr) 2024 (in INR Cr) 2023 (in INR Cr)
Sales
N.D 9.55 9.29
EBITDA
N.D
PAT
N.D
Business Documents